How Much Does Wegovy Cost Without Insurance in 2026?

Wegovy is a brand-name subcutaneous injection of semaglutide 2.4 mg manufactured by Novo Nordisk. The FDA approved it in June 2021 for chronic weight management in adults with obesity (BMI 30 or higher) or overweight (BMI 27 or higher) with at least one weight-related comorbidity. In March 2024, the FDA approved a second indication: reducing the risk of major adverse cardiovascular events in adults with established cardiovascular disease plus obesity or overweight, based on the SELECT trial results. That cardiovascular approval opened the door to Medicare Part D coverage for the first time.

Wegovy is self-administered via a once-weekly subcutaneous injection pen. Because patients inject it at home, it is billed as a pharmacy benefit under Medicare Part D or a commercial drug plan, not as a Part B medical benefit administered in a clinical setting. There is no dedicated HCPCS J-code for Wegovy. Dose titration starts at 0.25 mg weekly and steps up over 16 to 20 weeks to the 2.4 mg maintenance dose. List price is the same at all dose strengths.

No FDA-approved generic semaglutide exists as of 2026. Novo Nordisk's composition-of-matter patents are not expected to enable a biosimilar or generic competitor until approximately 2031. Compounded semaglutide copies were widely available from 503A pharmacies and 503B outsourcing facilities during the shortage period (2022 to early 2025). The FDA removed injectable semaglutide from its drug shortage list in February 2025. After the shortage ended, the FDA required 503A pharmacies to stop compounding semaglutide by April 22, 2025, and 503B outsourcing facilities by May 22, 2025. Legally obtained compounded semaglutide is no longer available from compliant pharmacies; purchasing it from non-FDA-registered sources carries significant safety risk. For the tirzepatide alternative, see Mounjaro cost. Medicaid GLP-1 coverage for obesity varies by state.

What Wegovy Costs by Point of Pay (2026)

The price you pay depends almost entirely on WHERE you pay. The same wegovy can cost many times more at a hospital than at your local pharmacy:

Why Hospitals Charge So Much

Wegovy is dispensed through retail or mail-order pharmacies as a self-administered drug, so hospital inpatient markups are rare in practice. The main pricing problem for Wegovy patients is the gap between the $1,349 list price and what is actually available without insurance. That gap exists because Novo Nordisk sets its Wholesale Acquisition Cost (WAC) high to accommodate rebates negotiated by pharmacy benefit managers on behalf of insurers. Uninsured cash-pay patients receive no PBM rebate and end up paying near the list price at retail pharmacies unless they use the NovoCare program.

GoodRx and other coupon aggregators typically show prices of $1,280 to $1,310 for Wegovy 2.4 mg at major chains, representing little meaningful discount from the list price. The NovoCare Pharmacy is the most significant discount channel for uninsured patients: $349 per month standard versus $1,349 at list. Mark Cuban's Cost Plus Drugs does not currently carry Wegovy. The practical pharmacy comparison for an uninsured patient in 2026 is between the NovoCare self-pay price ($349/month) and the full list price at a standard retail pharmacy ($1,349/month). No other widely available lower-cost channel exists for uninsured patients.

If Wegovy is administered in a clinical setting during an inpatient stay (uncommon, but possible during obesity medicine or bariatric consultations), the facility may bill under J3490 (unclassified injectable drug). In that context, a facility markup of 50% to 200% over acquisition cost is typical for high-cost specialty drugs. A month supply at a hospital acquisition cost of $800 to $1,000 could appear as $1,500 to $2,800 on an inpatient bill. Patients who see such a charge on a hospital bill should request an itemized bill and compare the line to the current NovoCare self-pay price as a benchmark for a dispute.

Patient Assistance Programs

Novo Nordisk does not include Wegovy in its standard low-income Patient Assistance Program (PAP) as of 2026. The Novo Nordisk PAP applies to products like Ozempic for type 2 diabetes, but not to Wegovy for weight management. The primary cost-reduction options for uninsured patients are the NovoCare self-pay pharmacy and, for commercially insured patients, the Novo Nordisk savings card:

Medicare Part D

Wegovy is covered under Medicare Part D for the cardiovascular risk reduction indication approved by the FDA in March 2024. Part D plans may cover Wegovy for adults with established cardiovascular disease (such as prior heart attack or stroke) plus obesity (BMI 30 or higher) or overweight (BMI 27 or higher). Medicare does not cover Wegovy for weight loss alone because anti-obesity medications have been excluded from the Part D formulary mandate since the program began. Coverage for the cardiovascular indication is subject to the standard 2026 Part D $2,100 annual out-of-pocket cap.

Starting July 1, 2026, CMS launched the Medicare GLP-1 Bridge, a temporary demonstration program running through December 31, 2027. The Bridge expands Wegovy access to Medicare Part D enrollees who meet one of three BMI-based eligibility tiers: (1) BMI at least 35 with no additional comorbidity required; (2) BMI at least 30 with a diagnosis of heart failure with preserved ejection fraction, uncontrolled hypertension defined as systolic blood pressure above 140 mm Hg or diastolic above 90 mm Hg while on two antihypertensive medications, or chronic kidney disease stage 3a or above; or (3) BMI at least 27 with a diagnosis of pre-diabetes, previous myocardial infarction, previous stroke, or symptomatic peripheral artery disease. Simple obesity alone does not qualify for the Bridge. The BMI requirement applies at the time of GLP-1 therapy initiation, not the time of the prior authorization request.

The GLP-1 Bridge copay is $50 per month at all dose strengths, including titration doses. This $50 copay does not count toward the 2026 Part D annual $2,100 out-of-pocket cap. The Low-Income Subsidy (Extra Help) does not apply to the Bridge copay. Prior authorization is required and processed centrally by Humana, the current LI NET program administrator. The Bridge covers Wegovy (injection and tablet) along with Zepbound and Foundayo. After December 31, 2027, coverage reverts to the cardiovascular-indication-only standard unless Congress passes permanent legislation.

Common Wegovy Billing Errors

Wegovy billing errors tend to occur in four areas: plan denials based on incorrect indication coding, savings card rejections, wrong Part B vs. Part D channel, and GLP-1 Bridge authorization errors. If your claim was denied or you were charged more than expected, check for these issues first:

• Denied as weight-loss drug when cardiovascular indication was documented: If your provider included the cardiovascular diagnosis (ICD-10 codes for established atherosclerotic cardiovascular disease) and the claim was still denied as an excluded anti-obesity drug, file an appeal citing the March 2024 FDA SELECT trial approval and the cardiovascular ICD-10 code on the prescription.
• Savings card rejected for government plan members: The Wegovy commercial savings card is not available to Medicare, Medicaid, VA, TRICARE, or any other federal program enrollee. This restriction applies even if you are paying out-of-pocket. If the pharmacy ran the card and it was rejected, verify which insurance you are enrolled in and switch to the NovoCare self-pay program instead.
• Prior authorization missing or expired at dose increase: Virtually all payers require prior authorization for Wegovy. PA typically must be renewed at each dose step-up. A fill at a new dose strength without a refreshed PA will reject. Confirm PA covers the specific dose before each fill.
• GLP-1 Bridge denied due to missing comorbidity documentation: The Bridge requires specific comorbidities, not just an elevated BMI. If a prior authorization was denied for the GLP-1 Bridge, verify that the prescribing provider submitted documented evidence of the qualifying comorbidity (HFpEF, uncontrolled hypertension on two agents, CKD stage 3a+, pre-diabetes, prior MI, prior stroke, or symptomatic PAD) alongside the BMI measurement.
• GLP-1 Bridge copay incorrectly applied to Part D OOP cap: The $50 monthly Bridge copay does not count toward the $2,100 annual Part D out-of-pocket cap. If your plan's EOB (Explanation of Benefits) shows the Bridge copay credited toward your OOP accumulator, notify member services, as this will create an accounting error in your annual cap tracking.

Frequently Asked Questions